×
About 333 results

ALLMedicine™ Acute Bronchospasm Center

Research & Reviews  24 results

Unusual Presentation of Atrial Myxoma: A Case Report and Review of the Literature.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105743
The American Journal of Case Reports; Jaravaza DR, Lalla U et. al.

May 4th, 2021 - BACKGROUND Although rare, atrial myxoma is the most common benign cardiac tumor. The recognized triad of presenting symptoms relates to constitutional, embolic, and obstructive effects produced by the tumor. However, the presentation may be non-sp...

Computed Tomography Scan Evidence of Bronchospasm and Its Resolution During Computed To...
https://doi.org/10.1213/XAA.0000000000001388
A&A Practice; Munaf M, Gadhinglajkar S et. al.

Mar 9th, 2021 - Bronchospasm in children is common; however, due to its sudden nature, radiographic correlation is uncommon. We planned a computed tomography (CT) coronary angiogram for a 5-year-old child for evaluation of Kawasaki disease. The child started to d...

Tissue traction microscopy to quantify muscle contraction within precision-cut lung sli...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052683
American Journal of Physiology. Lung Cellular and Molecul... Ram-Mohan S, Bai Y et. al.

Nov 28th, 2019 - In asthma, acute bronchospasm is driven by contractile forces of airway smooth muscle (ASM). These forces can be imaged in the cultured ASM cell or assessed in the muscle strip and the tracheal/bronchial ring, but in each case, the ASM is studied ...

FDA approves benralizumab autoinjector for eosinophilic asthma
https://www.mdedge.com/pulmonary-health-hub/article/209478/asthma/fda-approves-benralizumab-autoinjector-eosinophilic?channel=94
Christopher Palmer

Oct 4th, 2019 - The Food and Drug Administration has approved a prefilled, single-use autoinjector of benralizumab (Fasenra) for self-administration in adults with eosinophilic asthma, according to a press release from AstraZeneca. Benralizumab is already approve.

Incidence of acute bronchospasm during systemic adenosine administration for coronary a...
https://doi.org/10.4997/JRCPE.2019.307
The Journal of the Royal College of Physicians of Edinburgh; Morrow A, Ford TJ et. al.

Sep 10th, 2019 - Adenosine is frequently used during coronary angiography to induce hyperaemia and allow operators to perform quantitative measurements of lesion severity. Acute bronchospasm is a recognised side effect relating to the activation of 'off target' A2...

see more →

Drugs  96 results see all →

News  13 results

FDA approves benralizumab autoinjector for eosinophilic asthma
https://www.mdedge.com/pulmonary-health-hub/article/209478/asthma/fda-approves-benralizumab-autoinjector-eosinophilic?channel=94
Christopher Palmer

Oct 4th, 2019 - The Food and Drug Administration has approved a prefilled, single-use autoinjector of benralizumab (Fasenra) for self-administration in adults with eosinophilic asthma, according to a press release from AstraZeneca. Benralizumab is already approve.

FDA approves Nucala’s new at-home formulations
https://www.mdedge.com/pulmonary-health-hub/article/202475/asthma/fda-approves-nucalas-new-home-formulations?channel=188
Christopher Palmer

Jun 6th, 2019 - The Food and Drug Administration has approved two new formulations for the anti–interleukin-5 biologic mepolizumab (Nucala) for treatment of certain severe or rare forms of asthma, according to a press release from the drug’s developer. The biolog.

FDA approves triple-therapy inhaler for COPD
https://www.mdedge.com/familymedicine/article/147500/pulmonology/fda-approves-triple-therapy-inhaler-copd
Pulmonary Health Hub; Lucas Franki

Sep 19th, 2017 - The Food and Drug Administration has approved Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), a triple-therapy inhaler for the treatment of chronic obstructive pulmonary disease (COPD) in adult patients, according to a press release.

Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensure
http://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure

What is the purpose of the Surrogate Endpoint Table? FDA’s surrogate endpoint table provides valuable information for drug developers on endpoints that may be considered and discussed with FDA for individual development programs. This table also f...

FDA Expands Omalizumab (Xolair) to Younger Kids With Allergic Asthma
https://www.medscape.com/viewarticle/865952

Jul 11th, 2016 - The US Food and Drug Administration (FDA) has approved expanded use of omalizumab (Xolair, Novartis) to children as young as 6 years of age with uncontrolled moderate to severe persistent allergic asthma who have a positive skin test result or in ...

see more →